Clinical Trials in Minneapolis

Showing 5121-5140 of 14,456 trials

QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

NCT02384954

This is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation study of N-803 in patients with relapse/refractory indolent B cell non-Hodgkin lymphoma in conjunction with rituximab.

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma

Altor BioScience43 participantsStarted Apr 2015

Minneapolis, Minnesota, United States • St Louis, Missouri, United States • Columbus, Ohio, United States +1 more locations

COMPLETEDPhase 4< 1 mile

A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders

NCT02246218

This is an open-label study consisting of a transition period to RAVICTI, followed by a safety extension period for at least 6 months and up to 24 months of treatment with RAVICTI, depending on age at enrollment. It is designed to capture information important for evaluating safety, pharmacokinetics and efficacy in young children. Subjects who are followed by or referred to the Investigator for management of their UCD. Subjects eligible for this study will include patients ranging from newborn to \< 2 years of age with either a diagnosed or clinically suspected UCD.

Urea Cycle Disorder

Amgen27 participantsStarted Dec 2014

Los Angeles, California, United States • Palo Alto, California, United States • Washington D.C., District of Columbia, United States +14 more locations

QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders

Find Trials by Condition in Minneapolis

Teaching Loved Ones to Help Veterans Optimize Their PTSD Care and Healing

PRescribing INterventions for Chronic Pain Via the Electronic Health Record Study - Primary Care Providers

R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia

Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial

An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease

Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study

Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus

Fibricheck Detection cApabilities for Atrial Fibrillation

Small-Volume Tubes to Reduce Anemia and Transfusion

Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor

Prednisone in Cystic Fibrosis Pulmonary Exacerbations

Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas

Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy

A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer